Serum lipoprotein(a) is not modified by interleukin-6 receptor antagonism or associated with inflammation in non-ST-elevation myocardial infarction

被引：10

作者：

Ueland, Thor ^{[1
,2
,12
]}

Kleveland, Ola ^{[9
,10
]}

Michelsen, Annika E. ^{[1
,2
]}

Wiseth, Rune ^{[9
,10
]}

Damas, Jan Kristian ^{[11
]}

Holven, Kirsten B. ^{[7
,8
]}

Aukrust, Pal ^{[1
,2
,3
,12
]}

Gullestad, Lars ^{[2
,4
,5
,6
]}

Yndestad, Arne ^{[1
,2
,5
,6
]}

Halvorsen, Bente ^{[1
,2
]}

机构：

[1] Natl Hosp Norway, Internal Med Res Inst, Oslo Univ Hosp, Oslo, Norway

[2] Natl Hosp Norway, Inst Clin Med, Oslo Univ Hosp, Oslo, Norway

[3] Natl Hosp Norway, Sect Clin Immunol & Infect Dis, Oslo Univ Hosp, Oslo, Norway

[4] Natl Hosp Norway, Dept Cardiol, Oslo Univ Hosp, Oslo, Norway

[5] Univ Oslo, KG Jebsen Ctr Cardiac Res, Oslo, Norway

[6] Oslo Univ Hosp, Ctr Heart Failure Res, Oslo, Norway

[7] Dept Endocrinol Morbid Obes & Prevent Med, Norwegian Natl Advisory Unit Familial Hypercholes, Oslo, Norway

[8] Univ Oslo, Inst Basic Med Sci, Dept Nutr, Fac Med, Oslo, Norway

[9] St Olavs Hosp, Clin Cardiol, Trondheim, Norway

[10] Norwegian Univ Sci & Technol NTNU, Dept Circulat & Med Imaging, Trondheim, Norway

[11] Norwegian Univ Sci & Technol NTNU, Ctr Mol Inflammat Res, Dept Canc Res & Mol, Trondheim, Norway

[12] Univ Tromso, KG Jebsen TREC, Tromso, Norway

来源：

INTERNATIONAL JOURNAL OF CARDIOLOGY | 2019年 / 274卷

关键词：

Lipoprotein(a); Acute coronary syndrome; IL-6; antagonism; Inflammation; RHEUMATOID-ARTHRITIS; RISK; PROTEINS; DISEASE;

D O I：

10.1016/j.ijcard.2018.06.093

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Background: The IL-6 receptor antagonist tocilizumab has been shown to attenuate the proatherogenic lipoprotein a [Lp(a)] in rheumatoid arthritis. We evaluated if a single dose of tocilizumab reduced Lp(a) in patients with non-ST-elevation myocardial infarction (NSTEMI). Methods: Lp(a) was assessed by immunoassay (n = 117 patients) at 7 consecutive time-points between day 1 and 3 and at 3 and 6 months follow-up. Results: Tocilizumab did not affect Lp(a) at any time-point during the study and was not associated with cardiovascular risk factors. Conclusions: Short-time inhibition of IL-6 with tocilizumab in patients with NSTEMI did not influence Lp(a) levels. (c) 2018 Published by Elsevier B.V.

引用

页码：348 / 350

页数：3

共 50 条

[1] Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
Kleveland, Ola
Ueland, Thor
Kunszt, Gabor
Bratlie, Marte
Yndestad, Arne
Broch, Kaspar
Holte, Espen
Ryan, Liv
Amundsen, Brage H.
Bendz, Bjorn
Aakhus, Svend
Espevik, Terje
Halvorsen, Bente
Mollnes, Tom E.
Wiseth, Rune
Gullestad, Lars
Aukrust, Pal
Damas, Jan Kristian
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 271 : 1 - 7
[2] Serum Magnesium Is Associated with Long-Term Survival of Non-ST-Elevation Myocardial Infarction Patients
Segev, Amitai
Shechter, Michael
Tsur, Avishai M.
Belkin, David
Cohen, Hofit
Sharon, Amir
Morag, Nira Koren
Grossman, Ehud
Maor, Elad
NUTRIENTS, 2023, 15 (19)
[3] Cytokine pattern in patients with ST-elevation myocardial infarction treated with the interleukin-6 receptor antagonist tocilizumab
Woxholt, Sindre
Ueland, T.
Aukrust, Pal
Anstensrud, Anne Kristine
Broch, Kaspar
Tollefsen, Ingvild Maria
Ryan, Liv
Bendz, Bjorn
Hopp, Einar
Klow, Nils-Einar
Seljeflot, Ingebjorg
Halvorsen, Bente
Dahl, Tuva B.
Huse, Camilla
Andersen, Geir Oystein
Gullestad, Lars
Wiseth, Rune
Amundsen, Brage H.
Damas, Jan Kristian
Kleveland, Ola
OPEN HEART, 2023, 10 (02):
[4] Randomized Trial of Interleukin-6 Receptor Inhibition in Patients With Acute ST-Segment Elevation Myocardial Infarction
Broch, Kaspar
Anstensrud, Anne Kristine
Woxholt, Sindre
Sharma, Kapil
Tollefsen, Ingvild Maria
Bendz, Bjorn
Aakhus, Svend
Ueland, Thor
Amundsen, Brage Hoyem
Damas, Jan Kristian
Berg, Erlend Sturle
Bjorkelund, Elisabeth
Bendz, Christina
Hopp, Einar
Kleveland, Ola
Stensaeth, Knut Haakon
Opdahl, Anders
Klow, Nils-Einar
Seljeflot, Ingebjorg
Andersen, Geir Oystein
Wiseth, Rune
Aukrust, Pal
Gullestad, Lars
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2021, 77 (15) : 1845 - 1855
[5] Prognostic value of serum levels of interleukin-6 in patients with ST-segment elevation acute myocardial infarction
Borrayo-Sanchez, Gabriela
Pacheco-Bouthillier, Alex
Mendoza-Valdez, Lorena
Isordia-Salas, Irma
Argueero-Sanchez, Ruben
Careaga Reyna, Guillermo
CIRUGIA Y CIRUJANOS, 2010, 78 (01): : 25 - 30
[6] Cardiac sarcoidosis mimicking non-ST-elevation myocardial infarction
Uijlings, Ruben
Balt, Jippe C.
Boom, Paul
Wever, Eric
JOURNAL OF CARDIOVASCULAR MEDICINE, 2012, 13 (04) : 277 - 280
[7] Statin use is associated with less ST-elevation versus non-ST-elevation myocardial infarction in a nationwide study
Simony, Sofie B.
Langsted, Anne
Mortensen, Martin B.
Nordestgaard, Borge G.
Afzal, Shoaib
ATHEROSCLEROSIS, 2024, 399
[8] New anticoagulant options ST-elevation myocardial infarction and unstable angina pectoris/non-ST-elevation myocardial infarction
Bates E.R.
Current Cardiology Reports, 2007, 9 (4) : 289 - 297
[9] Temporal change in glucose tolerance in non-ST-elevation myocardial infarction
Srinivas-Shankar, U.
Somauroo, J. D.
Delduca, A. -M.
Jordan, T. S.
Bowles, S. A.
Rutter, M. K.
DIABETES RESEARCH AND CLINICAL PRACTICE, 2008, 82 (03) : 310 - 316
[10] Red blood cell distribution width is associated with myocardial injury in non-ST-elevation acute coronary syndrome
Tenekecioglu, Erhan
Yilmaz, Mustafa
Yontar, Osman Can
Bekler, Adem
Peker, Tezcan
Karaagac, Kemal
Ozluk, Ozlem Arican
Agca, Fahriye Vatansever
Kuzeytemiz, Mustafa
Senturk, Muhammed
Aslan, Burhan
Topal, Dursun
CLINICS, 2015, 70 (01) : 18 - 23

← 1 2 3 4 5 →